The Bionics Institute, a world leader in the development of novel medical bionics products, is proud to announce that it has appointed Dr Erol Harvey as Strategic Advisor to the Institute to assist in our goal of translating ground breaking early technology advancements into clinically validated products to transform lives of patients with debilitating diseases.

Dr Erol Harvey (BSc (Hons), PhD, FTSE, CEng) has been involved in the commercial and scientific development of micro and nano technology for more than 30 years. In 2002 he was a founder of MiniFAB (Australia) and was CEO until retirement on 31 December 2017. MiniFAB is a major Australian success story as a world leading product developer and precision engineering manufacturing company. MiniFAB’s client base includes multinational companies, venture capital-funded start-ups, international medical device companies, and university spin outs from around the world who contract MiniFAB to work on the practical implementation and commercialisation of novel science in areas such as biosensors, micro-fluidics and polymer micro-engineering.

Dr Harvey was elected a Fellow of the Australian Academy of Technology and Engineering (ATSE) for his services in the commercialisation of nano and micro technologies. He has served on several professional committees including the Micro and Nano Technology Commercialisation and Education Foundation (MANCEF) and the Australian Federal Government’s Future Manufacturing Industry Innovation Council (FMIIC). He recently served on the International Review Committee of the Eu0.7B German Helmholtz Micro-Nano Program and is a frequently invited speaker on innovation, commercialisation and University/Industry collaboration.

Dr Harvey will work closely with the Institute’s scientific and commercial team to develop manufacturing strategies for our technologies and develop focused pathways for translation from bench to clinical validation.

Dr Harvey said, “I have long admired the Bionics Institute as a team of uniquely talented multidisciplinary researchers combining engineering, electronics, biology and clinical interface. Their solutions to the real-world problems in neurology, hearing, vision, metabolic disease and inflammatory bowel disease have enormous potential. I am extremely excited to assist them as they translate their work into products that will make a positive change to people’s lives.”

Mr Robert Klupacs CEO of Bionics Institute said, “We are extremely fortunate to have someone of Erol’s reputation, skill and knowledge join us, especially given the interest in his skills and services since his retirement from MiniFAB. His achievements over the past 30 years speak for themselves and he will make a major contribution to our vision of translating medical bionics technologies to clinically important products. Combined with the recent appointments of Professor Hugh McDermott as Chief Technology Officer and Associate Professor James Fallon as Research Director of the Institute, and our team of talented researchers, we are now well positioned to make significant contributions to the lives of patients and Australian innovation”.